Skin Cancer

In a recent review, authors explored the effects of targeted therapies and immune checkpoint inhibitors on melanoma, particularly in minimal residual disease.

With the advent of immunotherapy, the 1-year survival rate for patients with metastatic melanoma has increased from 25% to 50%.

Patients in the clinical trial had confirmed disease progression after 12 weeks.

Researchers said the pandemic played a role in healthcare providers’ ability to safely and promptly treat various skin cancers.

There are currently no FDA approved therapies in this treatment setting.

The UK and Netherlands study assessed tumor response rates among 91 patients.

DermaSensor’s handheld device is awaiting FDA review.

Researchers were unable to determine a definite correlation.

Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

The use of tanning beds has become a popular practice in society today, however, it remains undisputed that ultraviolet radiation from natural sunlight and indoor tanning machines increases an individual’s risk of developing skin cancer.

Patients with squamous cell carcinoma who experience immunosuppression are at a greater risk.

Anna Bar, MD, FAAD returns to AAD as part of the interactive “How Would You Reconstruct It?” session.

Click here to answer this week's poll.

The commander-in-chief’s cancerous tissue was successfully removed last month.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses basal cell carcinoma and Mohs surgery related to Jill Biden's most recent skin cancer diagnosis.

Nivolumab for completely resected stage IIB or IIC melanoma is also validated by the European Medicines Agency.

The drug used to treat several dermatological disorders has immunosuppressive effects and has been linked with photosensitizing properties.

Recent research highlighted the important role of the skin’s microbiota in maintaining the homeostasis of the skin and the potential role the human microbiota may play in the development of skin cancer.

A poster presentation from SBS 2023 reviewed the clinician satisfaction of tirbanibulin for the treatment of actinic keratosis.

Laura Ferris, MD, PhD, discusses the future landscape of artificial intelligence and skin cancer detection at SBS 2023.

David Goldberg, MD, JD, explores the increasing rates of melanoma in the US and how to manage melanoma subtypes at SBS 2023.

Merkel cell carcinoma is a rare but highly aggressive type of nonmelanoma skin cancer and Merkel cell polyomavirus is thought to play a major role in its etiology.

The safety of gel manicures is under renewed scrutiny after a new study suggests they can cause DNA damage.

This review will explore various leukemia-related cutaneous findings and discuss the diagnosis and management of these conditions.

In his session at Maui Derm Hawaii 2023, Curtis Cole, PhD, President of Sun & Skin Consulting, LLC, detailed the limitations facing the US Sunscreen industry.